ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adalimumab"

  • Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting

    Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System

    Nobunori Takahashi1, Toshihisa Kojima2, Atsushi Kaneko3, Yuji Hirano4 and Naoki Ishiguro1, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, 3Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…
  • Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis

    Rubén Burgos-Vargas1, Shirley M.L. Tse2, Gerd Horneff3, Aileen L. Pangan4, Kristina Unnebrink5 and Jaclyn K. Anderson4, 1Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 2Pediatric Rheumatology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 3Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…
  • Abstract Number: 2366 • 2013 ACR/ARHP Annual Meeting

    Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study

    Yoshiya Tanaka1, Yasuhiko Shinmura2, Ryo Nakajima2, Takahiro Muramatsu2, Shuichi Komatsu3, Tadamichi Kubo2, Aki Kuroki4, Ataru Igarashi5, Toshiro Tango6 and Tsutomu Takeuchi7, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, 3Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, 4Medical Affairs, AbbVie GK, Tokyo, Japan, 5Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, 6Center for Medical Statistics, Tokyo, Japan, 7Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive…
  • Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting

    Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor

    Kirsten Minden1, Klaus Tenbrock2, Gerd Horneff3 and Hans-Iko Huppertz4, 1Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, 2University Aachen, Aachen, Germany, 3Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4Prof. Hess Childrens Hospital, Bremen, Germany

    Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
  • Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial

    Josef S. Smolen1, Ronald F. van Vollenhoven2, Roy Fleischmann3, Paul Emery4, Stefan Florentinus5, Suchitrita S. Rathmann6, Anabela Cardoso7, Hartmut Kupper8 and Arthur Kavanaugh9, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2The Karolinska Institute, Stockholm, Sweden, 3University of Texas Southwestern Medical Center, Dallas, TX, 4Leeds Teaching Hospital, Leeds, United Kingdom, 5AbbVie, Rungis, France, 6AbbVie Inc., North Chicago, IL, 7AbbVie, Amadora, Portugal, 8AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, 9University of California, San Diego, La Jolla, CA

    Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
  • Abstract Number: 483 • 2013 ACR/ARHP Annual Meeting

    Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study

    Sandra L Goss1, Cheri E Klein1, Hartmut Kupper2, Gerd Burmester3 and Walid Awni1, 1AbbVie Inc., North Chicago, IL, 2AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, 3Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany

    Background/Purpose: Higher exposure and lower immunogenicity rates have been observed for adalimumab when co-administered with methotrexate (MTX) compared to adalimumab monotherapy. The CONCERTO study was…
  • Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting

    Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis

    Sarah Thomas1, Nabeel Borazan2, Lewei Duan3, Nashla Barroso4, Sara Taroumian5, Banjamin Kretzmann6, Ricardo Bardales6 and Daniel Furst1, 1Medicine, University of California, Los Angeles, Los Angeles, CA, 2Medicine, Rheumatology UCLA, Los Angeles, CA, 3David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, 4Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, 5Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 6Rheumatology, University of California Los Angeles, los angeles, CA

    AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
  • Abstract Number: 488 • 2013 ACR/ARHP Annual Meeting

    The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration

    Walid Awni1, Sabine Pilari2, Ghada Ahmed3 and Peter Noertersheuser2, 1AbbVie Inc., North Chicago, IL, 2AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 3AbbVie, North Chicago, IL

    Background/Purpose:  Co-administration of methotrexate (MTX) has a significant effect on the pharmacokinetics (PK) of adalimumab (ADAL). MTX may impact the PK of other drugs by…
  • Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting

    Primary Human Cell BioMAP® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures

    Seng-Lai Tan1, Alison O'Mahony2, Ellen L. Berg2, Kandeepan Ganeshalingam3 and Ernest H. Choy4, 1Inflammation, Hoffmann-La Roche, Nutley, NJ, 2BioSeek, South San Francisco, CA, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…
  • Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting

    A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C

    Ying-Ming Chiu1, Chao-Hsiung Tang2, Sheng-Tzu Hung3, Ya-Wen Yang4, Chi-Hui Fang4 and Hsiao-Yi Lin5, 1Changhua Christian Hospital, Changhua City, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Formosa Biomedical Technology Corp., Taipei, Taiwan, 4Pfizer Limited, Taipei, Taiwan, 5Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…
  • Abstract Number: 1826 • 2013 ACR/ARHP Annual Meeting

    Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding

    Bohdan P. Harvey and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
  • Abstract Number: 494 • 2013 ACR/ARHP Annual Meeting

    Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis

    Petra Budde1, Angelika Lueking1, Carmen Theek1, Peter Schulz-Knappe1, Jacqueline Detert2, Gerd Burmester3 and Matthias Schneider4, 1Protagen AG, Dortmund, Germany, 2Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 3Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 4Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany

    Background/Purpose: Novel therapeutic concepts in early rheumatoid arthritis (ERA) are aiming for an early intervention and effective control of disease activity reaching remission. Most current…
  • Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting

    Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients

    Francisco Ortiz-Sanjuan1, Vanesa Calvo-Río2, Ricardo Blanco3, Emma Beltrán4, Juan Sánchez-Bursón5, Marina Mesquida6, Alfredo M. Adan6, M Hernandez Grafella7, E Valls Pascual8, L Martínez-Costa9, Agustí Sellas-Fernàndez10, Miguel Cordero-Coma11, Manuel Diaz-llopis12, David Salom12, Jl García Serrano13, Norberto Ortego13, JM Herreras14, Alejandro Fonollosa15, A Aparicio16, O Maíz17, A Blanco18, I Torre19, Cruz Fernández-Espartero20, V Jovani21, D Peitado-Lopez22, Esperanza Pato23, J Cruz24, J. Carlos Fernandez-Cid25, E. Aurrecoechea26, M García27, M Caracuel28, Carlos Montilla29, A Atanes30, F Francisco31, S Insua32, S González-Suárez33, A Sánchez-Andrade34, F Gamero35, Luis Linares36, F Romero-Bueno37, AJ García González38, Raquel Almodovar39, E Minguez40, C Carrasco Cubero41, Alejandro Olive Marques42, J Vázquez43, O Ruiz Moreno44, F Jimenez-Zorzo44, J Manero44, Javier Loricera1 and Miguel Angel González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Hospital Marques de Valdecilla, Santander, Spain, 4Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 5Hospital de Valme. Sevilla, Sevilla, Spain, 6Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, 8Rheumatology, Hospital Peset Valencia, Valencia, Spain, 9Ophthalmology, Hospital Peset Valencia, Valencia, Spain, 10Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, 11Departament of Ophthalmology, Hospital de León, León, Spain, 12Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, 13Hospital San Cecilio. Granada, Granada, Spain, 14Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, 15Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain, 16Rheumatology., Hospital de Toledo., Toledo, Spain, 17Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, 18Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, 19Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, 20Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, 21Rheumatology., Hospital General de Alicante., Alicante, Spain, 22Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, 23Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, 24Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, 25Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, 26Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 27Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, 28Rheumatology., Hospital de Córdoba., Córdoba, Spain, 29Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, 30Rheumatology., HUCA La Coruña., A Coruña, Spain, 31Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, 32Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 33Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, 34Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, 35Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, 36Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, 37Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, 38Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, 39Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, 40Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, 41Rheumatology., Hospital de Mérida, Mérida, Spain, 42Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, 43Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, 44Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain

    Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…
  • Abstract Number: 497 • 2013 ACR/ARHP Annual Meeting

    Development Of a Novel Bispecific Therapeutic For Arthritic Diseases

    Mathieu Ferrari1, Shimobi Onuoha1, Tahereh Kamalati2, Daniele Sblattero3 and Costantino Pitzalis4, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London, London, United Kingdom, 2University College of London, London, United Kingdom, 3University of Eastern Piedmont, Novara, Italy, 4Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom

    Background/Purpose: Despite the obvious success of current biological agents for treatment of rheumatoid arthritis (RA), achievement of broader efficacy and improved safety profile remains an…
  • Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting

    Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study

    Ghada Ahmed1, Sandra L Goss1, Cheri E Klein1, Neelufar Mozaffarian2, Gurjit S. Kaeley3 and Walid Awni1, 1AbbVie Inc., North Chicago, IL, 2Eli Lilly, San Diego, CA, 3College of Medicine, University of Florida, Jacksonville, FL

    Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology